Marico's Q1 FY26 results resurface: revenue rose 23.3% as India growth accelerated; Plix stake lifted to 60% in August move
Marico's Q1 FY26 consolidated revenue of Rs 3,259 crore, up 23.3% year on year, is resurfacing from an August 2025 report, alongside net profit rising 8.2% to Rs 513 crore. India revenue grew 27.2% and international revenue 12.9%. The company also increased its fully diluted stake in Plix maker Satiya Nutraceuticals to 60% as of that August 2025 move, deepening its health and wellness play.
What happened
Marico reported strong Q1 FY26 growth led by India core portfolios, foods and digital-first brands. It raised its holding in Plix maker Satiya Nutraceuticals to
Key facts
- Q1 FY26 consolidated net profit Rs 513 crore, up 8.2% YoY
- Revenue from operations Rs 3,259 crore, up 23.31% YoY
- India revenue Rs 2,495 crore, up 27.17% YoY
- International revenue Rs 764 crore, up 12.91% YoY
- Marico increased its stake in Satiya Nutraceuticals to 60% on a fully diluted basis
Why this matters
Increasing ownership of Plix to 60% gives Marico greater control over a high-growth wellness platform and creates a clearer path to integrate capabilities, channels and innovation into its portfolio.
What to watch
- India volume growth versus price-led growth in the next two quarters.
- Gross-margin and EBITDA-margin trend, especially commentary on copra, edible oils, crude derivatives and packaging inputs.
- Plix revenue growth, offline distribution expansion, profitability and any change in Marico's ownership or consolidation impact.
- Advertising-and-promotion spending as a percentage of sales.
- International business growth, particularly Bangladesh, Vietnam, MENA and South Africa demand conditions.
- Competitive response from large FMCG and nutrition brands in value-added foods and wellness.
- Scale Plix through Marico's distributor network, e-commerce capabilities and cross-category wellness bundles.
- Increase advertising and innovation behind premium foods, health, personal care and digital-first brands.
- Take calibrated price increases or reduce promotional intensity if key commodity costs rise further.
- Pursue additional minority stakes or partnerships in health, nutrition and adjacent premium consumption categories.
- Prioritize India growth investments while using international market expansion to diversify demand and currency exposure.